Aspiriant LLC’s TCW Transform 500 ETF VOTE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.8M Buy
167,619
+35,588
+27% +$3.04M 0.36% 38
2026
Q1
$10.1M Buy
132,031
+1,255
+1% +$100K 0.29% 44
2025
Q4
$10.5M Buy
130,776
+25,217
+24% +$2.01M 0.3% 43
2025
Q3
$8.28M Buy
105,559
+3,312
+3% +$250K 0.25% 45
2025
Q2
$7.44M Buy
102,247
+8,704
+9% +$585K 0.24% 49
2025
Q1
$6.12M Buy
93,543
+9,408
+11% +$650K 0.21% 52
2024
Q4
$5.79M Buy
84,135
+23,642
+39% +$1.63M 0.21% 53
2024
Q3
$4.06M Buy
60,493
+41,177
+213% +$2.66M 0.15% 59
2024
Q2
$1.23M Hold
19,316
0.05% 126
2024
Q1
$1.18M Hold
19,316
0.05% 135
2023
Q4
$1.07M Hold
19,316
0.05% 141
2023
Q3
$963K Hold
19,316
0.05% 137
2023
Q2
$997K Hold
19,316
0.05% 133
2023
Q1
$919K Hold
19,316
0.05% 137
2022
Q4
$854K Hold
19,316
0.04% 140
2022
Q3
$803K Hold
19,316
0.04% 133
2022
Q2
$845K Hold
19,316
0.04% 132
2022
Q1
$1.02M Hold
19,316
0.06% 128
2021
Q4
$1.08M Hold
19,316
0.06% 127
2021
Q3
$984K Buy
+19,316
New +$1.01M 0.06% 120

Other funds holding VOTE

Aspiriant LLC's VOTE Position: Q2 2026 in Review

Aspiriant LLC increased its TCW Transform 500 ETF (VOTE) stake by 27% in Q2 2026, buying an estimated $3.04M and bringing the position to 167,619 shares worth $14.8M. The position accounts for 0.36% of the portfolio, ranked #38.

Aspiriant LLC first reported a position in VOTE in Q3 2021 and has held it in 20 quarters since. 112 funds tracked by Wall St. Rank hold VOTE as of Q2 2026.

  • Aspiriant LLC held 167,619 shares of TCW Transform 500 ETF worth $14.8M as of Q2 2026.
  • Aspiriant LLC bought 35,588 TCW Transform 500 ETF shares in Q2 2026, an estimated $3.04M.
  • TCW Transform 500 ETF made up 0.36% of Aspiriant LLC's portfolio in Q2 2026, its #38 holding.
  • Aspiriant LLC first reported a position in TCW Transform 500 ETF in Q3 2021 and has held it in 20 quarters since.
  • 112 funds tracked by Wall St. Rank held TCW Transform 500 ETF as of Q2 2026.

Based on Aspiriant LLC's 13F filing for Q2 2026, filed 20 Jul 2026.